Nice & Green supports LIDDS Pharma with up to 40.8 million SEK in funding to secure new partnerships based on the NanoZolid® technology
Nice & Green, the Swiss investment firm, announces today the signing of a financing agreement of up to 40.8 million SEK with LIDDS pharma, a Swedish pharmaceutical company with a unique drug delivery based on the technology NanoZolid® technology. The new investment partnership between Nice & Green and LIDDS Pharma is manifested via a flexible Convertible Bonds program for an amount of up to SEK 10,200,000 per tranche over a period of up to 18 months. The funding secured by Nice & Green will allow LIDDS to further advance the project in clinical development, creating a solid foundation for new partnerships and license agreements based on the NanoZolid ® technology.
“This financing agreement provides LIDDS with important flexibility supporting fast progress of important project development steps in the company”, said Nina Herne CEO of LIDDS. “N&G is a dedicated investor, with a long-term commitment and a strong network of international institutional investors and family offices which is beneficial for LIDDS”, she continued.
Marc Cattelani, CEO of Nice & Green added: “The successful proprietary NanoZolid® technology platform developed by LIDDS is positively shaping the future of injectable drugs for cancer and other diseases. Today, with LIDDS’ decision to move to the Nasdaq Stockholm Main Market, and the financial flexibility provided by our financing program, we are confident LIDDS’ management team will achieve remarkable milestones for patients around the world.”
About LIDDS Pharma
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. Find out more at liddspharma.com.
About Nice & Green SA
Nice & Green is a privately held Swiss investment firm providing innovative and tailor-made equity financing solutions for small and mid-sized listed companies. Nice & Green helps ambitious companies secure the funding needed for their growth and strives to create value for both companies and their communities of shareholders, thanks to a virtuous approach for investment. Find out more at nicengreen.ch.
Contact Information
Michèle Aouad
Head of Marketing and Communications
maouad@nicengreen.ch
+41 22 361 36 97